IBD: Switching metabolism-can two drugs be better than one?

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 8, 2010, Pages 420-422

  Sparrow, Miles P ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; ALLOPURINOL; AMINOSALICYLIC ACID; AZATHIOPRINE; INOSINE TRIPHOSPHATE; MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

BLOOD CELL COUNT; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; FATIGUE; GENE MUTATION; HEPATITIS; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MYALGIA; NAUSEA; NODULAR HYPERPLASIA; OPTIMAL DRUG DOSE; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN OCCLUSION;

6-MERCAPTOPURINE; ALLOPURINOL; ANTIMETABOLITES; AZATHIOPRINE; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 77955462122     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.96     Document Type: Short Survey

References (10)

1. Gearry, R. B. et al. Thiopurine drug adverse effects in a population of new Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 13, 563-567 (2004).
2. sparrow, M. P., Hande, s. A., Friedman, s., Cao, D.&Hanauer, s. B. effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5, 209-214 (2007).
3. Ansari, A. et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 31, 640-647 (2010).
4. Derijks, L. J.&wong, D. R. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr. Pharm. Des. 16, 145-154 (2010).
5. Ansari, A. et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28, 734-741 (2008).
6. Dubinsky, M. C. et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125, 298-303 (2003).
7. Leung, Y., sparrow, M. P., schwartz, M.&Hanauer, s. B. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J. Crohns Colitis 3, 162-167 (2009).
8. smith, M. A. et al. novel pharmacogenetic markers for treatment outcome in azathioprinetreated inflammatory bowel disease. Aliment. Pharmacol. Ther. 30, 375-384 (2009).
9. Marinaki, A. M. et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (iTPase). Pharmacogenetics 14, 181-187 (2004).
10. elion, G. B., Kovensky, A.&Hitchings, G. H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem. Pharmacol. 15, 863-880 (1966).